Hormone replacement therapy in postmenopausal women: Breast tissue perfusion determined with MR imaging - Initial observations

Radiology

Volumn 235, Issue 1, 2005, Pages 36-41

  Delille, Jean Paul ^a   Slanetz, Priscilla J ^b   Yeh, Eren D ^a   Kopans, Daniel B ^a   Halpern, Elkan F ^a   Garrido, Leoncio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; GADOLINIUM PENTETATE MEGLUMINE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BREAST; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; INFORMED CONSENT; INJECTION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; PRIORITY JOURNAL; TISSUE PERFUSION;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE;

EID: 15944387749     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2351040012     Document Type: Article

References (41)

1. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317:1169-1174.
2. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993; 95(5A):37S-39S.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
4. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313:1044-1049.
5. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332:1758-1766.
6. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002; 137:273-284.
7. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288:872-881.
8. Sambrook M, Bamber JC, Minasian H, Hill CR. Ultrasonic Doppler study of the hormonal response of blood flow in the normal human breast. Ultrasound Med Biol 1987; 13:121-129.
9. Madjar H, Vetter M, Prompeler HJ, Wieacker P, Schillinger H. The normal vascularization of the female breast in Dopplet ultrasound. Ultraschall Med 1992; 13:171-177. [German]
10. Nelson TR, Pretorius DH, Schiffer LM. Menstrual variation of normal breast NMR relaxation parameters. J Comput Assist Tomogr 1985; 9:875-879.
11. Martin B, el Yousef SJ. Transverse relaxation time values in MR imaging of normal breast during menstrual cycle. J Comput Assist Tomogr 1986; 10:924-927.
12. Fowler PA, Casey CE, Cameron GG, Foster MA, Knight CH. Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging. Br J Obstet Gynaecol 1990; 97:595-602.
13. Dean KI, Majurin ML, Komu M. Relaxation times of normal breast tissues: changes with age and variations during the menstrual cycle. Acta Radiol 1994; 35:258-261.
14. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclicalphase dependency. Radiology 1997; 203:137-144.
15. Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203:145-149. [Erratum: Radiology 1997; 204:583.]
16. Berkowitz JE, Gatewood OM, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990; 174:199-201.
17. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990; 174:487-490.
18. Marugg RC, van der Mooren MJ, Hendriks JH, Rolland R, Ruijs SH. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur Radiol 1997; 7:749-755.
19. Leung W, Goldberg F, Zee B, Sterns E. Mammographic density in women on postmenopausal hormone replacement therapy. Surgery 1997; 122:669-673; discussion 673-674.
20. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997; 15:3201-3207.
21. Porfiri LM, Costanza L, De Felice C, Perrone G, David V, Zichella L. A mammographic evaluation of the morphostructural variations of the breast during hormone-replacement therapy in the postmenopause. Radiol Med (Torino) 1998; 95:573-576. [Italian]
22. Ozdemir A, Konus O, Nas T, Erbas G, Cosar S, Isik S. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet 1999; 67:23-32.
23. Reichenbach JR, Przetak C, Klinger G, Kaiser WA. Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 1999; 23:407-413.
24. Heywang SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95-103.
25. Heywang SH, Hilbertz T, Beck R, Bauer WM, Eiermann W, Permanetter W. Gd-DTPA enhanced MR imaging of the breast in patients with postoperative scarring and silicon implants. J Comput Assist Tomogr 1990; 14:348-356.
26. Gilles R, Guinebretiere JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993; 188:473-478.
27. Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187:751-755.
28. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999; 10:254-259.
29. Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197:33-38.
30. Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997; 205:837-842.
31. Zeppa R. Vascular response of the breast to estrogen. J Clin Endocrinol Metab 1969; 29:695-700.
32. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantification of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990; 16:117-131.
33. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265:1985-1990. [Erratum: JAMA 1991; 266:1362.]
34. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79:286-294.
35. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-1593.
36. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72:758-761.
37. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004; 230:29-41.
38. Roubidoux MA, Bailey JE, Wray LA, Helvie MA. Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. Radiology 2004; 230:42-48.
39. Delille JPJ, Slanetz PJ, Yeh ED, Foley MT, Kopans DB, Garrido L. Influence of the menstrual cycle on functional breast MRI (abstr). Radiology 2000; 217(P):526.
40. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10:382-393.
41. Potten CS, Watson RJ, Williams GT, et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58:163-170.